Renal function during therapy in patients with congestive cardiac failure. Ticrynafen vs. hydrochlorothiazide.

Abstract

14 patients with congestive heart failure requiring diuretic therapy were randomly assigned to treatment with ticrynafen (TCRN) 250 mg or hydrochlorothiazide (HCTZ) 50 mg once or twice daily. Both diuretics were effective and comparable in effecting a significant weight loss and increase in urinary sodium. The major difference between the two compounds was the marked fall in serum uric acid concentration and the increase in uric acid clearance occurring with ticrynafen. HCTZ caused an increase in serum uric acid and a fall in uric acid clearance. It is concluded that ticrynafen is a useful diuretic in the treatment of congestive heart failure and has the advantage of lowering serum uric acid rather than producing hyperuricemia.

• Authors: J W Smith, P Clements
• Journal: Nephron (Nephron) Vol. 23 Suppl 1 Pg. 41-5 ( 1979) ISSN: 1660-8151 [Print] Switzerland
• PMID: 381954 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Diuretics
• Phenoxyacetates
• Uricosuric Agents
• Hydrochlorothiazide
• Uric Acid

Topics

• Clinical Trials as Topic
• Diuretics (pharmacology, therapeutic use)
• Female
• Heart Failure (drug therapy)
• Humans
• Hydrochlorothiazide (pharmacology, therapeutic use)
• Male
• Middle Aged
• Natriuresis (drug effects)
• Phenoxyacetates (pharmacology, therapeutic use)
• Uric Acid (blood, urine)
• Uricosuric Agents (pharmacology, therapeutic use)